{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:13:59Z","timestamp":1774502039550,"version":"3.50.1"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,6,1]]},"DOI":"10.2169\/internalmedicine.2628-23","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T22:30:32Z","timestamp":1697754632000},"page":"1615-1621","source":"Crossref","is-referenced-by-count":4,"title":["Dabigatran-related Nephropathy Complicated by Tubulointerstitial Nephritis in a Patient with a Normal Renal Function and Undiagnosed IgA Nephropathy"],"prefix":"10.2169","volume":"63","author":[{"given":"Yoichi","family":"Iwafuchi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Koseiren Sanjo General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naofumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Koseiren Sanjo General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis 54: 1121-1126, 2009.","DOI":"10.1053\/j.ajkd.2009.04.024"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wheeler DS, Giugliano RP, Rangaswami J. Anticoagulation-related nephropathy. J Thromb Haemost 14: 461-472, 2016.","DOI":"10.1111\/jth.13229"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Krishna VN, Warnock DG, Saxena N, Rizk DV. Oral anticoagulants and risk of nephropathy. Drug Saf 38: 527-533, 2015.","DOI":"10.1007\/s40264-015-0290-z"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Brodsky SV, Satoskar A, Hemminger J, et al. Anticoagulant-related nephropathy in kidney biopsy: a single-center report of 41 cases. Kidney Med 1: 51-56, 2019.","DOI":"10.1016\/j.xkme.2019.03.002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Zakrocka I, Za\u0142uska W. Anticoagulant-related nephropathy: focus on novel agents. A review. Adv Clin Exp Med 31: 165-173, 2022.","DOI":"10.17219\/acem\/142657"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mitsuboshi S, Niimura T, Zamami Y, Ishizawa K. Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: analysis of the Japanese adverse drug event report database. Br J Clin Pharmacol 87: 2977-2981, 2021.","DOI":"10.1111\/bcp.14688"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Brodsky S, Eikelboom J, Hebert LA. Anticoagulant-related nephropathy. J Am Soc Nephrol 29: 2787-2793, 2018.","DOI":"10.1681\/ASN.2018070741"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 80: 181-189, 2011.","DOI":"10.1038\/ki.2011.44"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Medipally AK, Xiao M, Rovin BH, et al. Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy. Physiol Rep 9: e14697, 2021.","DOI":"10.14814\/phy2.14697"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ikeda M, Tanaka M, Shimoda S, et al. Dabigatran-induced anticoagulant-related nephropathy with undiagnosed IgA nephropathy in a patient with normal baseline renal function. CEN Case Rep 8: 292-296, 2019.","DOI":"10.1007\/s13730-019-00410-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Trujillo H, Sandino J, Cavero T, et al. IgA nephropathy is the most common underlying disease in patients with anticoagulant-related nephropathy. Kidney Int Rep 7: 831-840, 2022.","DOI":"10.1016\/j.ekir.2022.01.1048"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Moeckel GW, Luciano RL, Brewster UC. Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin. Clin Kidney J 6: 507-509, 2013.","DOI":"10.1093\/ckj\/sft076"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Escoli R, Santos P, Andrade S, Carvalho F. Dabigatran-related nephropathy in a patient with undiagnosed IgA nephropathy. Case Rep Nephrol 2015: 298261, 2015.","DOI":"10.1155\/2015\/298261"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kalaitzidis RG, Duni A, Liapis G, et al. Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity. Int Urol Nephrol 49: 1401-1407, 2017.","DOI":"10.1007\/s11255-017-1527-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sharfuddin N, Nourbakhsh M, Box A, Benediktsson H, Muruve DA. Anticoagulant related nephropathy induced by dabigatran. Case Rep Nephrol 2018: 7381505, 2018.","DOI":"10.1155\/2018\/7381505"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Li X, Cheung CY. Dabigatran causing severe acute kidney injury in a patient with liver cirrhosis. CEN Case Rep 8: 125-127, 2019.","DOI":"10.1007\/s13730-019-00378-4"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Miki\u010d TB, Kojc N, Frelih M, Ale\u0161-Rigler A, Ve\u010deri\u0107-Haler \u017d. Management of anticoagulant-related nephropathy: a single center experience. J Clin Med 10: 796, 2021.","DOI":"10.3390\/jcm10040796"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Margeti\u0107 S, Goreta S\u0160, \u0106elap I, Razum M. Direct oral anticoagulants (DOACs): from the laboratory point of view. Acta Pharm 72: 459-482, 2022.","DOI":"10.2478\/acph-2022-0034"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Medipally A, Xiao M, Biederman L, et al. Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Physiol Rep 10: e15343, 2022.","DOI":"10.14814\/phy2.15343"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Awesat J, Sagy I, Haviv YS, et al. Dabigatran-induced nephropathy and its successful treatment with Idarucizumab - case report and literature review. Thromb Res 169: 120-122, 2018.","DOI":"10.1016\/j.thromres.2018.07.019"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Galassi A, Podda G, Monciino P, et al. Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? A case report and proposal for a decisional algorithm. Clin Kidney J 14: 712-714, 2021.","DOI":"10.1093\/ckj\/sfaa011"},{"key":"22","unstructured":"22. Monahan RC, Suttorp MM, Gabre\u00ebls BATF. A case of rivaroxaban-associated acute tubulointerstitial nephritis. Neth J Med 75: 169-171, 2017."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Patel S, Hossain MA, Ajam M, et al. Dabigatran-induced acute interstitial nephritis: an important complication of newer oral anticoagulation agents. J Clin Med Res 10: 791-794, 2018.","DOI":"10.14740\/jocmr3569w"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Deng ZL, Yang WL, Zhao XY, et al. Simultaneous subacute interstitial nephritis and anticoagulant-related nephropathy related to novel oral anticoagulants use. Ren Fail 44: 30-33, 2022.","DOI":"10.1080\/0886022X.2021.2014338"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/11\/63_2628-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T03:34:42Z","timestamp":1717212882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/11\/63_2628-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2628-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"article-number":"2628-23"}}